A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer
Phase of Trial: Phase II
Latest Information Update: 05 May 2017
At a glance
- Drugs Rebamipide (Primary)
- Indications Mucositis
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 28 Apr 2016 Status changed from active, no longer recruiting to completed.
- 01 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
- 01 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 May 2016 as reported by ClinicalTrials.gov.